A
Antios Therapeutics
Innovative therapies to treat and cure hepatitis B virus (HBV) and other viral diseases
About Antios Therapeutics
Antios Therapeutics is a biopharmaceutical company focused on developing innovative therapies to treat and potentially cure hepatitis B virus (HBV) and other viral diseases. The company operates in the healthcare and pharmaceutical market, primarily targeting patients suffering from chronic HBV infections. Antios Therapeutics' core product includes ATI 2173, a novel compound combined with nucleoside analogues like Tenofovir or Entecavir, designed to inhibit HBV polymerase activity and viral replication. The company is also advancing its 4th generation capsid assembly modulator (CAM) program, which aims to enhance the immune system's ability to clear the virus more effectively. Antios Therapeutics generates revenue through the development and commercialization of its proprietary drug candidates, partnering with other biopharma companies for clinical trials and potential licensing agreements. The company serves a global market, addressing a significant unmet medical need with its cutting-edge antiviral therapies.
Source: Dealroom company dataAt a glance
- Founded
- 2018
- Headquarters
- Atlanta, United States
- Sector
- Biotech & Life Sciences
News
Open roles
Antios Therapeutics in the Atlanta ecosystem
The Antios Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A18 investors entered at this stage
Lumira Ventures
Domain Associates
Fonds de solidarité FTQ- CLCAM CAPITAL LIMITED
Delos Capital- SCSoleus Capital
Aisling Capital
Adage Capital
RA Capital Management
Altium Capital- GCGranite Point Capital
Pontifax Funds
LifeSci Venture Partners- AIAmzak Health Investors
CAM Capital
Sixty Degree Capital
EPIQ Capital Group
GordonMD Global Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Antios Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Antios Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

